Gilder Gagnon Howe & Co. LLC cut its position in shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) by 1.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,393,947 shares of the biopharmaceutical company’s stock after selling 20,684 shares during the period. Alnylam Pharmaceuticals accounts for 1.5% of Gilder Gagnon Howe & Co. LLC’s portfolio, making the stock its 12th largest position. Gilder Gagnon Howe & Co. LLC owned approximately 1.63% of Alnylam Pharmaceuticals worth $77,350,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Aperio Group LLC raised its stake in Alnylam Pharmaceuticals by 129.9% in the first quarter. Aperio Group LLC now owns 14,741 shares of the biopharmaceutical company’s stock worth $925,000 after buying an additional 8,328 shares during the period. BlackRock Inc. raised its stake in Alnylam Pharmaceuticals by 29.7% in the first quarter. BlackRock Inc. now owns 69,736 shares of the biopharmaceutical company’s stock worth $4,377,000 after buying an additional 15,965 shares during the period. BlackRock Group LTD raised its stake in Alnylam Pharmaceuticals by 21.9% in the first quarter. BlackRock Group LTD now owns 519,834 shares of the biopharmaceutical company’s stock worth $32,630,000 after buying an additional 93,450 shares during the period. BlackRock Fund Advisors raised its stake in Alnylam Pharmaceuticals by 6.5% in the first quarter. BlackRock Fund Advisors now owns 1,838,376 shares of the biopharmaceutical company’s stock worth $115,395,000 after buying an additional 112,252 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Alnylam Pharmaceuticals by 1.2% in the first quarter. JPMorgan Chase & Co. now owns 38,162 shares of the biopharmaceutical company’s stock worth $2,395,000 after buying an additional 450 shares during the period. Institutional investors and hedge funds own 85.95% of the company’s stock.

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) traded down 3.34% during mid-day trading on Wednesday, reaching $36.80. The company’s stock had a trading volume of 673,903 shares. The firm’s market capitalization is $3.15 billion. Alnylam Pharmaceuticals Inc. has a 12 month low of $33.16 and a 12 month high of $110.75. The company has a 50 day moving average of $63.40 and a 200-day moving average of $64.84.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.19. The business had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The firm’s revenue for the quarter was up .2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.85) earnings per share. Equities research analysts forecast that Alnylam Pharmaceuticals Inc. will post ($4.68) EPS for the current year.

ALNY has been the subject of a number of recent research reports. Zacks Investment Research upgraded Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 21st. JMP Securities restated a “buy” rating and set a $127.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, June 23rd. Jefferies Group restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, June 30th. Needham & Company LLC restated a “buy” rating and set a $152.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, July 1st. Finally, FBR & Co restated an “outperform” rating and set a $180.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, July 5th. Eight analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Alnylam Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $79.50.

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott acquired 27,900 shares of the company’s stock in a transaction dated Thursday, October 13th. The shares were acquired at an average cost of $37.00 per share, for a total transaction of $1,032,300.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.00% of the stock is owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

5 Day Chart for NASDAQ:ALNY

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.